How often should Benralizumab be administered?

Benralizumab is a monoclonal antibody used for the treatment of severe asthma and is known for its role in reducing eosinophil levels, which contributes to asthma pathology. The recommended administration schedule reflects its pharmacokinetics and clinical efficacy.

Initially, Benralizumab is administered every 4 weeks for the first three doses, and thereafter, it can be given every 8 weeks. This dosing schedule allows for adequate drug levels in the bloodstream to effectively manage asthma symptoms while minimizing the burden of frequent administration on the patient.

This approach balances treatment efficacy with patient compliance, as a more frequent administration could lead to reduced adherence to the treatment regimen. Additionally, the choice of every 4 weeks aligns with the therapeutic goals of ensuring consistent medication levels to maintain effective control of the patient’s asthma.